A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial-Reference-Cited by-同舟云学术

A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial

Published:2023-10 Issue:8 Volume:19 Page:684-694
ISSN:1774-024X
Container-title:EuroIntervention
language:
Short-container-title:

Author:

Kan Jing,Zhang Hang,Xie Dujiang,Wei Yongyue,Zhang Juan,Zhang Caojin,Yang Zhenwen,Gu Heping,Fan Fenling,Gu Hong,Wang Qiguang,Zhang Gangcheng,Guo Xiaomei,Yin Yuehui,Wang Xiang,Jin Bowen,Zhou Hongmei,Yang Ziyang,Wang Zhouming,Xin Yu,Zhang Chen,Meng Lili,Wang Xiaoyu,Zhao Chunxia,Yan Xiaoyan,Chen Feng,Yao Cheng,Stone Gregg W.,Chen Shao-Liang

Publisher

Europa Digital & Publishing

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States

2. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

3. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

4. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model

5. Survival in Patients with Primary Pulmonary Hypertension

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta‐analysis;ESC Heart Failure;2024-05-23

2. Pulmonary artery denervation – the suspense continues?;EuroIntervention;2023-10